Introduction
Vulvar cancer is the fourth most common malignancy in the female genital tract [1] . In Germany, 2,800-4,300 new cases are diagnosed per year, with a noticeable increase in recent years [2] . The majority of cases is diagnosed in stage I and II and the 5-year survival rate is 71% [2] . Most women are affected after the age of 70 years, with the mean age at diagnosis being 72 years in Germany [3] . However, the incidence in younger patients is increasing. This increase is disproportionate to the general rise in new cases and can also be observed internationally [3] [4] [5] [6] .
Human papillomavirus (HPV)-associated carcinomas occur more frequently in younger patients; cofactors such as smoking and immunosuppression also play a role in carcinoma development [2, 7, 8] . In women under 50 years, co-occurrence of vulvar cancer with other HPV-associated malignancies such as cervical and anal cancer has also been reported [9] . On the other hand, carcinomas in older patients are more often associated with chronic inflammatory skin diseases or lichen sclerosis and are HPV independent [2, 10] .
Most malignancies of the vulva are squamous cell carcinomas (90-95%), followed by basal cell carcinomas (approximately 5%); other tumours such as those of the Bartholin's glands are rare [1] [2] [3] .
The tumour stage, the lymph node (LN) status, and the complete surgical excision of the lesion, including the corresponding safety margins, are considered relevant prognostic factors. It remains unclear whether HPV association or keratinising vs. nonkeratinising squamous cell carcinomas are relevant for the prognosis [2] .
The present study analyses whether the clinical characteristics of patients below and above the age of 50 years differ from each other and whether the age at initial diagnosis has an influence on the disease-free survival (DFS).
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Patients and Methods
In a retrospective study, patients of 4 specialised hospitals who were treated for primary vulvar cancer from 2003 to 2015 were included. The age at diagnosis, the clinical data from the patients' records, and the follow-up data on recurrence and survival were recorded. The tumours were classified according to the TNM Classification, 7th edition [11] . DFS was calculated by the Kaplan-Meier analysis and the log-rank test. Differences between medians and frequencies within the groups were calculated by Mann-Whitney and Fisher's exact tests. The calculations were performed using the statistics program BiAS. for Windows TM [12] ; the level of significance was p = 0.05. Additionally, discriminant analysis was conducted to identify factors and their impact on the risk of recurrence. The elimination criterion was α = 0.15.
Results
Three hundred patients with vulvar carcinoma were included in the study. The median age was 64 years (19-96 years) . Most women were affected in their seventh and eighth decade, but a second smaller peak occurred after the age of 40 years ( fig. 1 ). Of the 300 patients, 79 patients were below 50 years of age (group I) and 221 were above 50 years of age (group II).
The majority of patients was diagnosed in early tumour stages. In 199 (66.3%) patients, T1 stage tumours were diagnosed. Of these, 61 were in group I and 138 in group II. However, the relative share of T1 tumours in group I (77.2%) was significantly higher than in group II (62.4%; p = 0.02).
In the present study, 85% of the tumours were locally limited T1 or T2 tumours. T2 tumours were found in 58 (19.3%) patients; of these, 8 (10.2%) were in group I and 50 (22.6%) were in group II (p = 0.02). Further, the 2 age groups did not differ in higher staged tumours (table 1) . Regarding histological grading, G2 tumours predominated in both groups: Group I had a G2 grading in 45.8% pa- tients, while G1 and G3 occurred in 3.2 and 8.7% patients, respectively, and in group II, 62% patients had G2, 6.3% had G1, and 23.1% patients had G3 (table 1) .
Partial vulvectomy was more common in the younger group I (82% vs. 60%; p < 0.01), whereas in group II, complete vulvectomy was more common (7.6% vs. 22.2%; p < 0.01). No differences were found regarding the LN status and the LN procedures: tumour-free LNs were found in 67% patients in group I, while 59% patients in group II had tumour-free nodes (table 1) .
Follow-up data were available for 135 patients (45%) with a median follow-up time of 52 months (3-154 months), of which 40 patients were below 50 years and 95 patients were above 50 years of age. Local recurrence was observed in 13 (32.5%) patients in group I and 19 (20.0%) patients in group II. Metastases were diagnosed in 3 of the younger patients (3.8%) and in 4 of the older ones (1.8 %). In 6 of these 7 cases, metastases were simultaneously diagnosed with local recurrence. At the time of follow-up, 67.5% of the younger patients and 80% of the patients of group II were tumour free. The median DFS for the 2 groups differed, with 209 weeks for group I and 491 weeks for Group II; this difference was not significant (p = 0.2) (fig. 2) . The age groups did not differ in tumour stages and grading. The number of locally advanced tumours in the group was too low to allow statistical analysis.
The nodal status and age at diagnosis had a significant influence on the DFS (fig. 3) . In both age groups, the prognosis deteriorated when LNs were affected. In N0 cases, the 5-year DFS in group I was 51.8%, but nil in cases of affected LNs. In group II, the 5-year DFS was 89.3% and 48.6% (p = 0.005) for N0 and N1, respectively. At the same time, the prognosis for patients with tumour-free nodes was better if they were above 50 years at diagnosis than for those 50 years of age (89% vs. 52%; p = 0.008), whereas this difference was not significant in patients with LN metastases.
The discriminant analysis confirmed that the risk of recurrence is lower in patients above the age of 50. Also, recurrence is more likely to occur in case of affected LNs and more advanced stages of tumour (table 2). 
Discussion
The present study regarding the prognosis of patients with early vulvar cancer revealed that the nodal status is the most important factor. Therefore, differences regarding DFS due to age at diagnosis only existed in patients without LN metastasis. Other factors, such as surgical procedure, tumour stage, or grading did not affect this.
The nodal status was identified as a prognostic factor for the DFS. This was true regardless of the patient's age and could be demonstrated individually in both groups as well as collectively for all the patients of the present study.
The median age of patients in the present study was 64 years, which was clearly below the German cancer registry figures (71 years of age); furthermore, the age distribution showed a higher number of younger patients in the present study [3] . It is conceivable that the assigning gynaecologists or the younger patients themselves favoured a hospital focussing on gynaecological oncology, which would influence the age structure accordingly. A SEER data analysis in the USA showed a similar age distribution to that in the present study, with a patient share of 19% for <50 years versus 26% for 50 years in the group here [5] .
In approximately two thirds of patients, cancer was diagnosed as a T1 tumour, which was found significantly more often in the younger patient group. This may be due to the fact that younger women pay more attention to their bodies or participate more regularly in PAPsmear screening for cervical cancer [13] , during which incidental vulvar carcinomas could be discovered by the examining gynaecologist.
These results correspond to the data found in the literature stating that vulvar cancer is diagnosed during early stages [1] . Furthermore, younger patients in Germany are diagnosed more often with early tumour stages [14] . While other studies have shown that more advanced tumour stages are mainly found in older patients [13, 15] , this could not be confirmed by the present data. The literature reports contradictory findings on the influence of age on prognosis: While Kumar et al. has observed an influence in his SEER data analysis [5] , others did not [16] .
In the present study, the DFS did not differ between the age groups for patients with affected LNs, suggesting that the nodal status as the most important independent prognostic factor for vulvar cancer [17] [18] [19] outweighs the age factor. This was different for patients with tumour-free LNs: In the present study, the DFS for patients >50 years was significantly better, even though there was a higher percentage of T2 tumours in this group. One explanation might be the different pathogenesis and different risk of recurrence of the tumours associated with HPV, which occur mainly in younger women. The debate on the likelihood of recurrence in HPV-associated carcinomas is controversial: Lanneau et al. points out that younger patients often smoke and have HPV infections [20] . Tobacco consumption and HPV infection increase the risk of developing vulvar cancer [21] [22] [23] , and the persistence of these factors also possibly increases the risk of recurrence. Recurrence rate is higher in pre-malignancies caused by HPV, but less progression to invasive tumours is observed. [24, 25] . However, some studies have shown that HPV indicates a less aggressive tumour form with less potential of recurrence [26, 27] . Other studies on HPV and recurrence risk also have contrary results [28] [29] [30] . Kashofer et al. found a higher rate of mortality for patients without HPV if TP53 gene mutation was seen. These patients also seem to respond less favourable on chemo-and radiotherapy [31] .
The present study was unable to show comprehensive evidence for HPV within its patients. Nevertheless, the contradictory findings suggest that assuming younger patients with vulvar carcinoma are suffering from HPV-dependent tumours is not correct, as age is an independent factor for the risk of recurrence. As the frequency of HPV-associated carcinomas has been rising over the past years, the role of HPV as an independent prognostic factor should be explored in further studies.
The present results contrast with the aforementioned SEER data analysis results, in which a better overall survival was shown for the group of patients <50 years in all tumour stages. However, the present group of patients was clearly different from the SEER patients; the share of patients with LN metastases (21%) and distant metastases (3%) was significantly lower. Furthermore, no differences were found between the groups regarding the tumour stages, whereas the frequency of advanced tumour stages (FIGO III/ IV) varied significantly between the groups in the study by Kumar et al. (26% vs. 39%) [5] , which, however, was not reproduced in another analysis of the SEER data [15] .
One explanation could lie in the different health care systems. While access to health care and preventive medical screening is available for the entire population in Germany, this is not the case in the USA. In the USA, it has been shown that hepatocellular carcinoma, for instance, is diagnosed in less advanced stages when comparing people with health insurance to people without insurance [32] .
Because younger patients in the American group have better survival in all tumour stages than older patients, it is unlikely that the difference is exclusively due to the higher proportion of advanced carcinomas in the patients >50 year [5] . Another reason might be the kind of treatment that was performed. The lower survival rate in patients >50 years can be due to the fact that older patients are often treated by radiotherapy rather than by surgery [33] .
In addition, elderly patients have a lower overall survival (OS) due to other age-associated diseases. Panici et al. showed a correlation between age and OS, but not with DFS [34, 35] . The relative survival, which is the difference in comparison with a non-affected sample patient group, was not analysed.
As the prognosis for early stage vulvar carcinoma is good, it was decided to analyse DFS rather than OS to show the influence that vulvar cancer itself has on the patients' prognosis.
Conclusion
LN metastases are the predominant prognostic factor in vulvar cancer. For patients below the age of 51 years with tumour-free LNs, there is a significantly higher recurrence risk than for older patients. Data on factors that may explain this, in particular HPV infections or tobacco consumption, are contradictory.
